Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab

Launched by REGINA ELENA CANCER INSTITUTE · Jan 10, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how effective a specific type of radiation therapy, called thoraco-mediastinal radiotherapy, is when combined with a medication called atezolizumab for patients with extensive small cell lung cancer. The goal is to see if this combination can help improve treatment outcomes for patients who have already received chemotherapy and immunotherapy and are showing some positive response to treatment.

To be eligible for this trial, participants should be at least 18 years old and have a confirmed diagnosis of small cell lung cancer. They should have had prior treatment and be in a stable condition with manageable side effects. Participants will undergo imaging tests to check their response to earlier treatments before starting the radiation therapy. Throughout the trial, patients can expect regular check-ups and monitoring to assess their health and response to the combined treatment. This study is currently recruiting, welcoming individuals of all genders who fit the criteria, and interested patients should discuss with their healthcare team to learn more.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological diagnosis of lung microcytoma;
• • Age ≥18 years;
• • Performance status according to ECOG 0-2;
• • Extended disease at the time of first line oncological treatment;
• • Initial staging and restaging after chemo-immunotherapy with CT, CT-PET FDG and brain MRI;
• • In at least partial response (defined according to the Recist criteria \[18\]) after treatment chemoimmunotherapy according to the Impower 133 scheme;
• • Haematological, respiratory toxicity ≤ G1, other toxicities ≤ G2 at the time of treatment radiotherapy;
• • Pulmonary function tests at the time of radiotherapy treatment compatible with irradiation: FEV≥1.2 l or \>40%, DLCO≥50%;
• • Written informed consent.
• Exclusion Criteria:
• • Previous radiotherapy treatment at the thoraco-mediastinal level;
• • In disease progression after chemo-immunotherapy treatment.